- 作者: Morris Ling; Masahide Kanayama; Richard Roden; T.-C. Wu
- 作者服務機構: Department of Pathology, Oncology, Obstetrics and Gynecology and Molecurlar Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, Md., USA
- 中文摘要: --
- 英文摘要: 'High risk' genotypes of the human papillomavirus(HPV), particularly HPV type 16, are the primary etiologicagent of cervical cancer. Thus, HPV-associated cervicalmalignancies might be prevented or treated by inductionof the appropriate virus-specific immune responses inpatients. Sexual transmission of HPV may be preventedby the generation of neutralizing antibodies that are spe-cific for the virus capsid. In ongoing clinical trials, HPVvirus-like particles (VLPs) show great promise as prophy-lactic HPV vaccines. Since the capsid proteins are notexpressed at detectable levels by basal keratinocytes,therapeutic vaccines generally target other nonstructuralviral antigens. Two HPV oncogenic proteins, E6 and E7,are important in the induction and maintenance of cellu-lar transformation and are coexpressed in the majority ofHPV-containing carcinomas. Therefore, therapeutic vac-cines targeting these proteins may provide an opportuni-ty to control HPV-associated malignancies. Various can-didate therapeutic HPV vaccines are currently beingtested whereby E6 and/or E7 are administered in live vec-tors, in peptides or protein, in nucleic acid form, as com-ponents of chimeric VLPs, or in cell-based vaccines.Encouraging results from experimental vaccination sys-tems in animal models have led to several prophylacticand therapeutic vaccine clinical trials. Should they fulfilltheir promise, these vaccines may prevent HPV infectionor control its potentially life-threatening consequences inhumans.
- 中文關鍵字: --
- 英文關鍵字: --